SCHEMBL966237

SCHEMBL966237

NC1=N[C@@]2(c3cc(F)cc(NC(=O)c4ccc(F)cn4)c3)COC[C@H]2CS1

nearest known ligand 0.74

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 20/20 0.74
BACE2 Q9Y5Z0 10/20 0.74
KCNH2 Q12809 4/20 0.52
CTSD P07339 1/20 0.52
CYP2D6 P10635 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL968228 0.99 BACE1 (0.73) BACE1BACE2KCNH2CTSDCYP2D6
SCHEMBL6878650 0.90 BACE1 (0.75) BACE1BACE2KCNH2CTSD
Hydrochloric Acid SCHEMBL971474 0.90 BACE1 (0.74) BACE1BACE2KCNH2CTSD
Hydrochloric Acid SCHEMBL968439 0.90 BACE1 (0.74) BACE1BACE2KCNH2CTSD
SCHEMBL970337 0.86 BACE1 (0.56) BACE1BACE2KCNH2CTSD
Ly-2886721 SCHEMBL966802 0.85 BACE1 (1.00) BACE1BACE2KCNH2CTSDCYP2D6
Ly-2886721 SCHEMBL18195437 0.85 BACE1 (1.00) BACE1BACE2KCNH2CTSDCYP2D6
Ly-2886721 SCHEMBL971344 0.85 BACE1 (1.00) BACE1BACE2KCNH2CTSDCYP2D6
Ly-2886721 SCHEMBL30477100 0.85 BACE1 (1.00) BACE1BACE2KCNH2CTSDCYP2D6
Ly-2886721 SCHEMBL31235710 0.84 BACE1 (0.98) BACE1BACE2KCNH2CTSDCYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2451793-B1 BACE INHIBITORS LILLY CO ELI (US) 2016-11-02 EP disclosed
EP-2451793-B1 BACE INHIBITORS LILLY CO ELI (US) 2016-11-02 EP disclosed
US-20120323001-A1 BACE INHIBITORS ELI LILLY AND COMPANY (US) 2012-12-20 US disclosed
US-20120323001-A1 BACE INHIBITORS ELI LILLY AND COMPANY (US) 2012-12-20 US disclosed
US-8278441-B2 BACE inhibitors ELI LILLY AND COMPANY (US) 2012-10-02 US disclosed
US-8278441-B2 BACE inhibitors ELI LILLY AND COMPANY (US) 2012-10-02 US disclosed
US-8278441-B2 BACE inhibitors ELI LILLY AND COMPANY (US) 2012-10-02 US disclosed
US-20110009395-A1 BACE INHIBITORS ELI LILLY AND COMPANY (US) 2011-01-13 US disclosed
US-20110009395-A1 BACE INHIBITORS ELI LILLY AND COMPANY (US) 2011-01-13 US disclosed
US-20110009395-A1 BACE INHIBITORS ELI LILLY AND COMPANY (US) 2011-01-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120323001-A1 BACE INHIBITORS BACE1, BACE2, APP BACE1 1/4885BACE2 2/4885KCNH2 3088/4885
US-20110009395-A1 BACE INHIBITORS BACE1, BACE2, APP BACE1 1/4885BACE2 2/4885KCNH2 3088/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.